The Future of Lymphedema: Potential Therapeutic Targets for Treatment.

IF 1 Q4 ONCOLOGY

Current Breast Cancer Reports Pub Date : 2023-06-01 DOI:10.1007/s12609-023-00491-5

Stav Brown, Adana C Campbell, Kevin Kuonqui, Ananta Sarker, Hyeung Ju Park, Jinyeon Shin, Raghu P Kataru, Michelle Coriddi, Joseph H Dayan, Babak J Mehrara

{"title":"The Future of Lymphedema: Potential Therapeutic Targets for Treatment.","authors":"Stav Brown, Adana C Campbell, Kevin Kuonqui, Ananta Sarker, Hyeung Ju Park, Jinyeon Shin, Raghu P Kataru, Michelle Coriddi, Joseph H Dayan, Babak J Mehrara","doi":"10.1007/s12609-023-00491-5","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review aims to summarize the current knowledge regarding the pharmacological interventions studied in both experimental and clinical trials for secondary lymphedema.Recent findings: Lymphedema is a progressive disease that results in tissue swelling, pain, and functional disability. The most common cause of secondary lymphedema in developed countries is an iatrogenic injury to the lymphatic system during cancer treatment. Despite its high incidence and severe sequelae, lymphedema is usually treated with palliative options such as compression and physical therapy. However, recent studies on the pathophysiology of lymphedema have explored pharmacological treatments in preclinical and early phase clinical trials.Summary: Many potential treatment options for lymphedema have been explored throughout the past two decades including systemic agents and topical approaches to decrease the potential toxicity of systemic treatment. Treatment strategies including lymphangiogenic factors, anti-inflammatory agents, and anti-fibrotic therapies may be used independently or in conjunction with surgical approaches.","PeriodicalId":10769,"journal":{"name":"Current Breast Cancer Reports","volume":" ","pages":"1-9"},"PeriodicalIF":1.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233555/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Breast Cancer Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12609-023-00491-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Purpose of review: This review aims to summarize the current knowledge regarding the pharmacological interventions studied in both experimental and clinical trials for secondary lymphedema.

Recent findings: Lymphedema is a progressive disease that results in tissue swelling, pain, and functional disability. The most common cause of secondary lymphedema in developed countries is an iatrogenic injury to the lymphatic system during cancer treatment. Despite its high incidence and severe sequelae, lymphedema is usually treated with palliative options such as compression and physical therapy. However, recent studies on the pathophysiology of lymphedema have explored pharmacological treatments in preclinical and early phase clinical trials.

Summary: Many potential treatment options for lymphedema have been explored throughout the past two decades including systemic agents and topical approaches to decrease the potential toxicity of systemic treatment. Treatment strategies including lymphangiogenic factors, anti-inflammatory agents, and anti-fibrotic therapies may be used independently or in conjunction with surgical approaches.

查看原文本刊更多论文

淋巴水肿的未来：潜在的治疗目标。

综述目的：本综述旨在总结目前在实验和临床试验中研究的继发性淋巴水肿药物干预的知识。最近的发现：淋巴水肿是一种进行性疾病，会导致组织肿胀、疼痛和功能残疾。在发达国家，继发性淋巴水肿最常见的原因是癌症治疗过程中对淋巴系统的医源性损伤。尽管淋巴水肿的发生率很高，后遗症也很严重，但它通常是通过压迫和物理治疗等姑息性选择来治疗的。然而，最近关于淋巴水肿病理生理学的研究已经在临床前和早期临床试验中探索了药物治疗。摘要：在过去的二十年里，已经探索了许多淋巴水肿的潜在治疗方案，包括全身药物和局部方法，以降低全身治疗的潜在毒性。治疗策略包括淋巴管生成因子、抗炎药和抗纤维化疗法可以单独使用或与手术方法结合使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Breast Cancer Reports ONCOLOGY-

CiteScore

1.60

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of breast cancer. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those with the disease. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as prevention, systemic therapy, and translational research. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.